Tuberculosis (TB)

Tuberculosis (TB) remains one of the world’s deadliest infectious diseases, claiming 1.25 million lives in 2023, nearly twice as many as HIV/AIDS, and affecting 10.8 million people. Yet, TB is preventable and curable when addressed through evidence-based interventions, technological innovation, and multisectoral collaboration.

PURPOSE

Our Mission

In Indonesia, TB remains the leading cause of death from infectious disease, claiming over 150,000 lives each year and affecting more than one million people. Drug-resistant TB (DR-TB) further complicates the response, requiring coordinated, people-centered, and equitable access to high-quality care. Yasa Karsa Insani (YKI) believes that ending TB is achievable through technical innovation, collaborative partnerships, and sustained system investment. Working alongside national and subnational stakeholders, Yasa Karsa Insani (YKI) translates global evidence into local action by strengthening prevention, early detection, treatment quality, and health system resilience.

Through evidence-based technical assistance, operational research, and digital transformation, Yasa Karsa Insani (YKI) supports the Ministry of Health and its partners to bridge gaps in TB care, ensuring that TB services are technically robust, cost-effective, and sustainable. All efforts are guided by value for money, results-based management, and a commitment to governance, accountability, and country ownership.

CAPABILITIES

Our Key Areas of Expertise

Translating Evidence into Policy and Practice

Yasa Karsa Insani (YKI) generates operational evidence and collaborates with national stakeholders to translate research into policy and program design, ensuring that innovations are scaled, integrated, and sustained within Indonesia’s TB response and contribute to evidence-informed decision-making.

Strengthening Clinical and Programmatic Management

Yasa Karsa Insani (YKI) enhances clinical and programmatic quality by supporting shorter, safer treatment regimens, improving pharmacovigilance systems, and promoting people-centered models of care that improve treatment adherence, safety, and people wellbeing.

Advancing Diagnostic and Laboratory Capacity

We strengthen laboratory systems and expand access to molecular and rapid diagnostic tools, ensuring timely, accurate, and equitable diagnosis for all. This includes supporting digital connectivity, quality assurance frameworks, and integration within the national laboratory network.

Enhancing Health Information and Digital Systems

Yasa Karsa Insani (YKI) promotes digital health transformation and data-driven decision-making, ensuring interoperability and real-time information flow across systems to strengthen surveillance, case management, and performance monitoring at all levels.

Strengthening Communities for Better Outcomes

Our programmes foster trust, literacy, and engagement among people affected by TB through rights-based, locally linked interventions that bridge facility and community platforms. This systems-oriented approach ensures that integrated and equitable care reaches those most in need while reinforcing continuity and accountability within the health system.

HIGHLIGHTED PROJECT

Our Work

LON – Mandiri TB

Yasa Karsa Insani (YKI) implemented Mandiri TB with USAID support to strengthen community capacity and resource mobilisation for DR-TB care, establishing multi-sector forums, training patient groups for counselling and monitoring, and increasing treatment enrolment with 383 patients enrolled, 420 cadres trained, and five CSR initiatives launched.

LIFT-TB

Yasa Karsa Insani (YKI), with support from KOICA and the TB Alliance through KNCV TB Foundation, implemented LIFT-TB to accelerate adoption of shorter, safer drug-resistant TB treatments in 15 hospitals. The project strengthened clinical and laboratory capacity, supported operational research, and achieved a 97.6% treatment success rate, leading to Indonesia’s national adoption of the WHO-recommended BPaL/M regimen.

One to Three Study

Yasa Karsa Insani (YKI), as the local sponsor in collaboration with the Aurum Institute, with Unitaid support through KNCV TB Foundation, implemented the One To Three Study (2022–2025), a phase IV randomised clinical trial at Persahabatan Hospital comparing the safety, completion, and feasibility of 1HP and 3HP tuberculosis preventive regimens, confirming both as safe, effective, and suitable for programmatic use in Indonesia.

HARAPAN

Yasa Karsa Insani (YKI), with support from the World Bank and Bill & Melinda Gates Foundation, implemented HARAPAN to strengthen private primary care providers’ capacity in TB financing and service delivery. The project enhanced case detection, data accuracy, provider collaboration, and increased treatment initiation in Bogor, Semarang, and Surabaya.